Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy. Issue 10 (22nd June 2015)

• Record Type: Journal Article
• Authors: Inzucchi, S. E.; Tunceli, K.; Qiu, Y.; Rajpathak, S.; Brodovicz, K. G.; Engel, S. S.; Mavros, P.; Radican, L.; Brudi, P.; Li, Z.; Fan, C. P. S.; Hanna, B.; Tang, J.; Blonde, L.
• Is Part Of: Diabetes, obesity & metabolism. Volume 17:Issue 10(2015:Oct.)
• Page Start: 956
• Page End: 964
• Publication Date: 2015-06-22
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12489
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12489-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="dom12489-sec-0001" sec-type="section"> <title>Aim</title> <p id="dom12489-para-0001">To assess time to insulin initiation among patients with type 2 diabetes mellitus (T2DM) treated with sitagliptin versus sulphonylurea as add‐on to metformin.</p> </sec> <sec id="dom12489-sec-0002" sec-type="section"> <title>Methods</title> <p id="dom12489-para-0002">This retrospective cohort study used GE Centricity electronic medical records and included patients aged ≥18 years with continuous medical records and an initial prescription of sitagliptin or sulphonylurea (index date) with metformin for ≥90 days during 2006–2013. Sitagliptin and sulphonylurea users were matched 1 : 1 using propensity score matching, and differences in insulin initiation were assessed using Kaplan–Meier curves and Cox regression. We used conditional logistic regression to examine the likelihood of insulin use 1–6 years after the index date for each year.</p> </sec> <sec id="dom12489-sec-0003" sec-type="section"> <title>Results</title> <p id="dom12489-para-0003">Propensity score matching produced 3864 matched pairs. Kaplan–Meier analysis showed that sitagliptin users had a lower risk of insulin initiation compared with sulphonylurea users (p = 0.003), with 26.6% of sitagliptin users initiating insulin versus 34.1% of sulphonylurea users over 6 years. This finding remained significant after adjusting for baseline characteristics (hazard ratio 0.76, 95% confidence interval 0.65–0.90). Conditional logistic regression analyses confirmed that sitagliptin users were less likely to initiate insulin compared with sulphonylurea users [odds ratios for years 1–6: 0.77, 0.79, 0.81, 0.57, 0.29 and 0.75, respectively (p < 0.05 for years 4 and 5)].</p> </sec> <sec id="dom12489-sec-0004" sec-type="section"> <title>Conclusions</title> <p id="dom12489-para-0004">In this real‐world matched cohort study, patients with T2DM treated with sitagliptin had a significantly lower risk of insulin initiation compared with patients treated with sulphonylurea, both as add‐on to metformin.</p> </sec> </abstract>